Program
Immunoglobulins, Intravenous
Also written as “NPB-01”, “TAK-881” and “IVIG”.
Its studies are mostly in Primary Immunodeficiency Diseases · Purpura, Thrombocytopenic, Idiopathic · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Immunologic Deficiency Syndromes · Myasthenia Gravis, led by 18 companies.
Drug pageImmunoglobulins, Intravenous: every studyMany companies study it; this page follows only the 83 they lead. All 227 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 203 open or running | phase 4since Apr 12, 2017 | Sep 8, 2005 | May 16, 2028phase 3 · NCT06076642 |
| Grifols | 172 open or running | phase 4since Oct 24, 2011 | Sep 13, 2005 | Dec 31, 2027phase 3 · NCT07540221 |
| Nihon Pharmaceuticalits history only | 80 open or running | phase 3since Jul 27, 2011 | Dec 11, 2008 | none ahead |
| Octapharmaits history only | 61 open or running | phase 3since Nov 11, 2009 | Nov 11, 2009 | Nov 2026phase 3 · NCT04640142 |
| CSLits history only | 51 open or running | phase 3since Oct 12, 2011 | Oct 12, 2011 | May 6, 2029phase 2 · NCT07048262 |
| Kedrionits history only | 53 open or running | phase 3since Apr 16, 2012 | Apr 16, 2012 | Dec 2026phase 3 · NCT07059000 |
| Japan Blood Products Organizationits history only | 40 open or running | phase 3since Jun 8, 2006 | Jun 8, 2006 | none ahead |
| GC Biopharmaits history only | 31 open or running | phase 3since Jul 26, 2011 | Jul 26, 2011 | none ahead |
| Prothya Biosolutionsits history only | 30 open or running | phase 4since Aug 29, 2007 | Aug 29, 2007 | none ahead |
| Azidus Brasilits history only | 22 open or running | phase 3since Sep 19, 2023 | Sep 19, 2023 | Sep 2028phase 3 · NCT06150833 |
| Benesisits history only | 20 open or running | phase 3since Jul 3, 2006 | Jul 3, 2006 | none ahead |
| Biopharma Plasmaits history only | 20 open or running | phase 3since Jul 15, 2020 | Jul 15, 2020 | none ahead |
| AstraZenecaits history only | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Dobri Kiprovits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Evolve Biologicsits history only | 10 open or running | phase 3since Jul 21, 2017 | Jul 21, 2017 | none ahead |
| GammaCanits history only | 10 open or running | phase 2since Feb 19, 2006 | Feb 19, 2006 | none ahead |
| IMMUNOe Research Centersits history only | 10 open or running | phase 4since Nov 14, 2017 | Nov 14, 2017 | none ahead |
| Isaac Melamedits history only | 10 open or running | phase 4since Jul 21, 2014 | Jul 21, 2014 | none ahead |
Also a collaborator on its studies: Takeda Development Center Americas, Baxalta Innovations GmbH, now part of Shire, Parexel, Premier Research Group and TFS Trial Form Support.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Grifols only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 13, 2005First studies: 3 phase 2 studiesFirst studyNCT00220779, NCT00220727, NCT00220805
- Sep 13, 20052 phase 3 studiesNCT00220766, NCT00220740
- Oct 17, 2006Phase 2 study in Immunologic Deficiency SyndromesNCT00389324 · 35 enrolled · United States, Canada
- Aug 1, 2007Phase 3 study in Purpura, Thrombocytopenic, IdiopathicNCT00511147 · 64 enrolled · United States, Canada, India and more
- Jun 16, 2008Phase 3 study in Purpura, ThrombocytopenicNCT00699140 · 18 enrolled · Russian Federation, Spain, United Kingdom
- Oct 24, 2011Phase 4 study in Primary Immunodeficiency DiseasesNCT01465958 · 12 enrolled · United States
- Jun 25, 2014Phase 3 study in Postpoliomyelitis SyndromeNCT02176863 · 191 enrolled · United States, Canada, Czechia and more
- Apr 7, 2015Phase 3 study in Myasthenia Gravis ExacerbationsNCT02413580 · 49 enrolled · Argentina, Belgium, Canada and more
- Jun 14, 20152 phase 2 studies in Myasthenia GravisNCT02473965, NCT02473952
- Nov 20, 2017Phase 4 study in Anti-Hepatitis A Antibody Levels in Heathy SubjectsNCT03351933 · 28 enrolled · United States
- Jun 12, 2020Phase 2 study in COVID-19NCT04432324 · 100 enrolled · Spain
- Apr 9, 20262 phase 3 studiesNCT07540221, NCT07582432
Ahead
- Dec 31, 2027Primary completion: phase 3 study in Polyradiculoneuropathy, Chronic Inflammatory DemyelinatingNCT07540221
- Aug 31, 2028Primary completion: phase 3 study in Leukemia, Lymphocytic, Chronic, B-CellNCT07582432
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 17 Grifols leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07582432Leukemia, Lymphocytic, Chronic, B-Cell · United States | 3 | Recruiting | Aug 31, 2028 | 49 |
| NCT07540221Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Czechia, Poland and more | 3 | Recruiting | Dec 31, 2027 | 40 |
| NCT04432324COVID-19 · Spain | 2 | Completed | Mar 3, 2021 | 100 |
| NCT03351933Anti-Hepatitis A Antibody Levels in Heathy Subjects · United States | 4 | Completed | Apr 27, 2018 | 28 |
| NCT02473965Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Feb 2019 | 60 |
| NCT02473952Myasthenia Gravis · United States, Belgium, Canada and more | 2 | Completed | Jan 2018 | 62 |
| NCT02413580Myasthenia Gravis Exacerbations · Argentina, Belgium, Canada and more | 3 | Completed | Apr 2018 | 49 |
| NCT02176863Postpoliomyelitis Syndrome · United States, Canada, Czechia and more | 3 | Terminated | Nov 24, 2022 | 191 |
| NCT01465958Primary Immunodeficiency Diseases · United States | 4 | Completed | Oct 2013 | 12 |
| NCT00699140Purpura, Thrombocytopenic · Russian Federation, Spain, United Kingdom | 3 | Completed | Dec 2013 | 18 |
| NCT00511147Purpura, Thrombocytopenic, Idiopathic · United States, Canada, India and more | 3 | Completed | Apr 2014 | 64 |
| NCT00389324Immunologic Deficiency Syndromes · United States, Canada | 2 | Completed | Aug 2008 | 35 |
| NCT00220805Macular Degeneration · Germany | 2 | Completed | May 2005 | 96 |
| NCT00220779Multiple Sclerosis, Relapsing-Remitting · United States, Austria, Canada and more | 2 | Completed | Feb 2005 | 128 |
| NCT00220766Immunologic Deficiency Syndromes · United States, Canada | 3 | Completed | Aug 2002 | 100 |
| NCT00220740Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Argentina, Canada and more | 3 | Completed | Jun 2006 | 117 |
| NCT00220727Purpura, Thrombocytopenic, Idiopathic · United States | 2 | Completed | Oct 2003 | 8 |
How it is read
Names in the registry
- “NPB-01”, 7 entries
- “TAK-881”, 6 entries
- “IVIG”, 6 entries
- “Kedrion IVIG 10%”, 4 entries
- “GB-0998”, 4 entries
Codes read as this program: TAK881, GC5107, GB0998.
Conditions, from the studies’ own filings
- Primary Immunodeficiency Diseases, 24 studies
- Purpura, Thrombocytopenic, Idiopathic, 6 studies
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating, 5 studies
- Immunologic Deficiency Syndromes, 4 studies
- Myasthenia Gravis, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.